Ariana Mullin

Company: Bristol Myers Squibb

Job title: Director - Regulatory Affairs

Seminars:

Panel Discussion | Moving the Gold Standard Beyond Subjective Mood Scales & Evaluating the Potential of Surrogate Endpoints 10:15 am

What are the right endpoints to use in indications, such as substance use disorder, where a defined mood scale is not clear? Critically evaluating the value of Hamilton and MADRS scales: are there different, more objective ways of tracking the severity of various psychological illnesses? Are we close to having a surrogate in psychiatry with…Read more

day: Conference Day 2 AM